Indrayani Biotech Limited has announced a significant development in its financial services portfolio. The company's wholly-owned subsidiary, IBL Investments Limited, has successfully obtained approval from the Securities and Exchange Board of India (SEBI) for a Category II Alternative Investment Fund (AIF) registration.

Key Details of the Approval

The approval grants IBL Investments Limited the authority to operate as a SEBI-registered Category II Alternative Investment Fund. This development marks a strategic expansion of Indrayani Biotech's financial services offerings through its subsidiary.

Significance of the Approval

The Category II AIF registration is a notable achievement for IBL Investments Limited and its parent company, Indrayani Biotech. Alternative Investment Funds are privately pooled investment vehicles that collect funds from sophisticated investors, whether Indian or foreign, for investing in accordance with a defined investment policy.

Category II AIFs can invest in a wide range of strategies, including private equity, debt funds, and fund of funds. This approval opens up new avenues for IBL Investments Trust to attract investments and potentially enhance its asset management capabilities.

Regulatory Compliance

Indrayani Biotech Limited has duly informed the BSE Limited about this development, adhering to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's prompt disclosure demonstrates its commitment to transparency and regulatory compliance.

Company Background

Indrayani Biotech Limited, headquartered in Chennai, is a diversified company with interests in various sectors. The expansion into alternative investment funds through its subsidiary indicates the company's efforts to diversify its revenue streams and strengthen its position in the financial services sector.

This strategic move by Indrayani Biotech, through its subsidiary IBL Investments Limited, positions the company to capitalize on the growing alternative investment market in India.

Indrayani Biotech Limited (IBL) has released its unaudited financial results for the first quarter, revealing a mixed performance across its standalone and consolidated operations.

Standalone Performance

On a standalone basis, IBL reported a marginal increase in net profit, which stood at ₹12.77 crore compared to ₹12.72 crore in the same quarter last year. However, the company's revenue saw a significant decline, dropping to ₹668.57 crore from ₹1,079.09 crore year-over-year, representing a decrease of approximately 38%.

Despite the revenue contraction, IBL managed to maintain its earnings per share (EPS) at ₹0.03, consistent with the previous year's Q1 performance.

Consolidated Results

The consolidated financial results paint a more challenging picture for Indrayani Biotech. Consolidated revenue decreased to ₹2,910.37 crore from ₹3,152.78 crore in the corresponding quarter, marking a decline of about 7.7%. More notably, the consolidated net profit saw a substantial drop, falling to ₹15.65 crore from ₹85.02 crore in the same period last year, representing a decrease of approximately 81.6%.

This significant reduction in profitability is reflected in the consolidated earnings per share, which fell to ₹0.03 from ₹0.10 in the previous year's first quarter.

Financial Highlights

Additional Information

The company's board meeting to approve these results was held on August 14, 2025. The statutory auditors have provided an unmodified opinion on both standalone and consolidated results, indicating that the financial statements present a fair and accurate view of the company's financial position.

Indrayani Biotech reported that no investor complaints were received during the quarter, suggesting positive investor relations despite the mixed financial performance.

The company's paid-up equity share capital remains unchanged at ₹455.36 crore, with a face value of ₹10 per share.

These financial results will be available on the company's website ( www.indrayani.com ) and on the BSE website for public access.